Analysts at StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL – Get Rating) in a research report issued to clients and investors on Saturday. The brokerage set a "sell" rating on the medical technology company's stock.
A number of other brokerages have also recently weighed in on BIOL. Benchmark reduced their price target on shares of BIOLASE to $7.00 in a research report on Wednesday, November 16th. Maxim Group reduced their price target on shares of BIOLASE from $10.00 to $5.00 in a research report on Friday, November 11th. Finally, Ascendiant Capital Markets reduced their price target on shares of BIOLASE to $14.00 in a research report on Wednesday, November 16th.
Get BIOLASE alerts:BIOLASE Price Performance
BIOL opened at $0.84 on Friday. The company has a fifty day moving average price of $1.83 and a two-hundred day moving average price of $3.41. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.27 and a current ratio of 2.46. BIOLASE has a 52 week low of $0.76 and a 52 week high of $13.83. The firm has a market capitalization of $6.00 million, a PE ratio of -0.24 and a beta of 1.34.
Institutional Investors Weigh In On BIOLASE
Institutional investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC bought a new stake in BIOLASE in the 2nd quarter valued at $118,000. Capital Wealth Alliance LLC bought a new stake in BIOLASE in the 2nd quarter valued at $51,000. Commonwealth Equity Services LLC lifted its position in BIOLASE by 117.8% during the 1st quarter. Commonwealth Equity Services LLC now owns 101,046 shares of the medical technology company's stock worth $35,000 after buying an additional 54,650 shares in the last quarter. Essex Investment Management Co. LLC lifted its position in BIOLASE by 62.3% during the 3rd quarter. Essex Investment Management Co. LLC now owns 105,318 shares of the medical technology company's stock worth $256,000 after buying an additional 40,440 shares in the last quarter. Finally, Perkins Capital Management Inc. lifted its position in BIOLASE by 11.6% during the 3rd quarter. Perkins Capital Management Inc. now owns 132,070 shares of the medical technology company's stock worth $321,000 after buying an additional 13,770 shares in the last quarter. 21.21% of the stock is owned by institutional investors.BIOLASE Company Profile
(Get Rating)
BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications.
Read More
- Get a free copy of the StockNews.com research report on BIOLASE (BIOL)
- Intel is a Sleeping Giant Ready to Awaken
- Why CSL Ltd Stock Could Be Worth a Look
- MarketBeat: Week in Review 11/28 – 12/02
- Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
- Institutions Are Buying Ambarella, Should You?
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.